Patient characteristics
| Previously untreated patients, age, y/sex . | Secondary or de novo . | Diagnostic karyotype . | Presenting WBC × 103/μL . | % BM blasts . | Response . |
|---|---|---|---|---|---|
| 81/F | De novo | 46,XX,del(5)(q13q33)(2)/46,sl,del(11)(p12)(cp2)/46,sl,t(X;6)(p22.1;q13),del(12)(p11.2), del(16)(q12.1)(15)/ nonclonal with clonal abnormalities(1) | 4.8 | 71 | CRi |
| 66/F | Secondary | Insufficient Metaphase (46,XX(6)/nonclonal(2)) | 1.5 | 48 | CR |
| 84/M | De novo | 85-88 < 4n >, XXYY,i(1)(q10),-2,-3,-7,-9,-17,i(17)(q10),+18(cp15)/46,XY(4)/8n(1) | 1 | 76 | |
| 65/F | De novo | Normal | 5.2 | 20 | CR |
| 68/M | De novo | 44,X-Y,-3,del(5)(q22q35),del(6)(q13), del(17)(p11.2)(5)/43,sl,-11,der(19)t(1 1;19) (q12;p13.3)(3)/44,sl,+mar1(cp3)/ 44,sl,add(19)(p13.3)(cp2)/44,sl,+mar2(2)/46,XY(5) | 0.5 | 14 | |
| 70/M | De novo | Normal | 11.3 | 65 | |
| 73/M | Secondary | 46,XY,del(7)(q21)(13)/46,XY(6)/nonclonal(1) | 39.8 | 39 | |
| 67/M | De novo | 43,XY,-3,del(5)(q13),-7,del(8)(p12), dic(11;12)(p11.2;p11.2), add(15)(p11.1), 16,add(17)(p11.2),+mar(18)/46,XY(1)/nonclonal(1) | 0.2 | 15 | |
| 70/M | De novo | 46,XY,inv(3)(q21q26)(10)/46,XY(10) | 0.5 | 23 | CR |
| 83/M | Secondary | 46,XY,del(12)(p11.2p13)(3)/45,idem,-7(22).ish del(12)(ETV6-) | 0.8 | 34 | CRu |
| Previously untreated patients, age, y/sex . | Secondary or de novo . | Diagnostic karyotype . | Presenting WBC × 103/μL . | % BM blasts . | Response . |
|---|---|---|---|---|---|
| 81/F | De novo | 46,XX,del(5)(q13q33)(2)/46,sl,del(11)(p12)(cp2)/46,sl,t(X;6)(p22.1;q13),del(12)(p11.2), del(16)(q12.1)(15)/ nonclonal with clonal abnormalities(1) | 4.8 | 71 | CRi |
| 66/F | Secondary | Insufficient Metaphase (46,XX(6)/nonclonal(2)) | 1.5 | 48 | CR |
| 84/M | De novo | 85-88 < 4n >, XXYY,i(1)(q10),-2,-3,-7,-9,-17,i(17)(q10),+18(cp15)/46,XY(4)/8n(1) | 1 | 76 | |
| 65/F | De novo | Normal | 5.2 | 20 | CR |
| 68/M | De novo | 44,X-Y,-3,del(5)(q22q35),del(6)(q13), del(17)(p11.2)(5)/43,sl,-11,der(19)t(1 1;19) (q12;p13.3)(3)/44,sl,+mar1(cp3)/ 44,sl,add(19)(p13.3)(cp2)/44,sl,+mar2(2)/46,XY(5) | 0.5 | 14 | |
| 70/M | De novo | Normal | 11.3 | 65 | |
| 73/M | Secondary | 46,XY,del(7)(q21)(13)/46,XY(6)/nonclonal(1) | 39.8 | 39 | |
| 67/M | De novo | 43,XY,-3,del(5)(q13),-7,del(8)(p12), dic(11;12)(p11.2;p11.2), add(15)(p11.1), 16,add(17)(p11.2),+mar(18)/46,XY(1)/nonclonal(1) | 0.2 | 15 | |
| 70/M | De novo | 46,XY,inv(3)(q21q26)(10)/46,XY(10) | 0.5 | 23 | CR |
| 83/M | Secondary | 46,XY,del(12)(p11.2p13)(3)/45,idem,-7(22).ish del(12)(ETV6-) | 0.8 | 34 | CRu |
Cru indicates unconfirmed complete remission for the elderly patient who had peripheral blood count recovery but who refused BM evaluation after treatment, as noted in the text; and WBC, white blood cell.